scholarly journals The Microbiota in Systemic Lupus Erythematosus: An Update on the Potential Function of Probiotics

2021 ◽  
Vol 12 ◽  
Author(s):  
Xirui Guo ◽  
Xuerong Yang ◽  
Qi Li ◽  
Xiaoyan Shen ◽  
Huiyun Zhong ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Animal Models ◽  
Lupus Erythematosus ◽  
Gut Microbiome ◽  
Inflammatory Responses ◽  
The Body ◽  
Comprehensive Treatment ◽  
Systemic Lupus ◽  
Novel Approach ◽  
Made In

Systemic lupus erythematosus (SLE) is a kind of chronic diffuse connective tissue illness characterized by multisystem and multiorgan involvement, repeated recurrence and remission, and the presence of a large pool of autoantibodies in the body. Although the exact cause of SLE is not thoroughly revealed, accumulating evidence has manifested that intake of probiotics alters the composition of the gut microbiome, regulating the immunomodulatory and inflammatory response, which may be linked to the disease pathogenesis. Particularly, documented experiments demonstrated that SLE patients have remarkable changes in gut microbiota compared to healthy controls, indicating that the alteration of microbiota may be implicated in different phases of SLE. In this review, the alteration of microbiota in the development of SLE is summarized, and the mechanism of intestinal microbiota on the progression of immune and inflammatory responses in SLE is also discussed. Due to limited reports on the effects of probiotics supplementation in SLE patients, we emphasize advancements made in the last few years on the function and mechanisms of probiotics in the development of SLE animal models. Besides, we follow through literature to survey whether probiotics supplements can be an adjuvant therapy for comprehensive treatment of SLE. Research has indicated that intake of probiotics alters the composition of the gut microbiome, contributing to prevent the progression of SLE. Adjustment of the gut microbiome through probiotics supplementation seems to alleviate SLE symptoms and their cardiovascular and renal complications in animal models, marking this treatment as a potentially novel approach.

The curious case of miR-155 in SLE

2021 ◽  
Vol 23 ◽  
Author(s):  
S. A. Ibrahim ◽  
A. Y. Afify ◽  
I. O. Fawzy ◽  
N. El-Ekiaby ◽  
A. I. Abdelaziz
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Immune System ◽  
Targeted Therapy ◽  
Animal Models ◽  
Autoimmune Diseases ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Recent Attention ◽  
Made In

Abstract Epigenetic modifications have been well documented in autoimmune diseases. MicroRNAs (miRNAs), in particular, have long intrigued scientists in the field of autoimmunity. Owing to its central role in the development of the immune system, microRNA-155 (miR-155) is deeply involved in systemic lupus erythematosus (SLE). Despite the advancements made in treating SLE, the disease still remains incurable. Therefore, recent attention has been drawn to the manipulation of epigenetics in the development of curative treatments. In fact, it is a widely held view that miRNA-targeted therapy is a new glimmer of hope in the treatment of autoimmune diseases. However, the duplicity of miRNAs should not be overlooked. A single miRNA can target several mRNAs, and some mRNAs may possess opposing functions. In this review, we highlight the role of miR-155 as a biomarker and review its functions in SLE patients and animal models while discussing possible reasons behind inconsistencies across studies.

scholarly journals The Current Concept of T H 17 Cells and Their Expanding Role in Systemic Lupus Erythematosus

Arthritis ◽  
2011 ◽  
Vol 2011 ◽  
pp. 1-10 ◽  
Author(s):  
Daniel Perry ◽  
Ammon B. Peck ◽  
Wendy C. Carcamo ◽  
Laurence Morel ◽  
Cuong Q. Nguyen
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Antinuclear Antibodies ◽  
Inflammatory Responses ◽  
Cell Lineage ◽  
Basement Membranes ◽  
The Body ◽  
Adaptive Responses ◽  
Systemic Lupus ◽  
Chronic Autoimmune Disease

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a multifaceted range of symptoms affecting almost every organ system. The prototypical pathology of SLE involves the production of antinuclear antibodies and the deposition of immune complexes in basement membranes throughout the body where they induce inflammatory responses. The genetic and environmental etiologies of this process are being intensively sought, and recently, T H 17 cells have been implicated in the pathogenesis of SLE. T H 17 cells are CD4+ memory T cells that behave as both helper and effector cell populations functioning through their signature IL-17 cytokines. Their differentiation is distinct to either the T H 1 or T H 2 cell lineage, but strongly influences development of adaptive responses, including autoimmunity. This paper details the biological functions and regulation of T H 17 cells, followed by an update of their expanding role in SLE.

scholarly journals Systemic Lupus Erythematosus Disease: An Overview of the Clinical Approach to Pathogenesis, Diagnosis, and Treatment

2021 ◽  
Vol 4 (2) ◽  
pp. 91-98
Author(s):  
Saurabh Nimesh ◽  
Md. Iftekhar Ahmad ◽  
Shikhka Dhama ◽  
Pradeep Kumar ◽  
Muhammad Akram ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Immune System ◽  
Chronic Disease ◽  
Lupus Erythematosus ◽  
The Body ◽  
Clinical Approach ◽  
Systemic Lupus Erythematosus Disease ◽  
Systemic Lupus ◽  
Organ Systems ◽  
Novel Approaches

The systemic lupus erythematosus (SLE), commonly known as Lupus, is a rare and complex multisystem autoimmune disease where one’s immune system is overactive, and the body attacks its organ systems. SLE is a historically old disease described already in antiquity; it is an example of a chronic disease with physical, psychological, financial, and social implications for individuals diagnosed. It has inspired medical and basic biological scientists that focus on molecular biology, basic immunology, immunopathology, clinical science, genetics, and epidemiology. The syndrome is real in its existence-although hidden behind obstacles, cumbersome for patients and clinicians, and rebellious for scientists. There is currently no cure for SLE. The goal of treatment is to ease symptoms. This article will review information on the general approach to SLE therapy, focusing on currently approved therapies and novel approaches that might be used in the future.

Management of special situations in systemic lupus erythematosus

2016 ◽  
Author(s):  
April Jorge ◽  
Rosalind Ramsey-Goldman
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Comprehensive Treatment ◽  
Systemic Lupus ◽  
Risk Factor Modification ◽  
Safety Issues ◽  
Increased Risk ◽  
Treatment Considerations ◽  
Pregnancy And Lactation ◽  
Adverse Pregnancy

In caring for patients with systemic lupus erythematosus (SLE), there are several important treatment considerations. Since many patients with SLE are female and of childbearing potential, it is important to address conception planning, contraceptive options, and the maternal and fetal risks associated with pregnancy, which are increased when there is higher SLE disease activity. It is also pertinent to address medication safety issues throughout pregnancy and lactation, as some commonly used medications can increase risks of adverse pregnancy outcomes. Additionally, patients with SLE are at higher risk for cardiovascular disease (CVD) than the general population. Therefore, these patients must undergo aggressive risk factor modification. Patients with SLE are also at increased risk for osteoporosis, and bone health is an important treatment consideration. Routine cancer screening and vaccinations are also important elements of the comprehensive treatment of the patient with SLE.

Withdrawal: Animal Models in Systemic Lupus Erythematosus

2014 ◽  
Vol 21 (6) ◽  
pp. 343
Author(s):  
Hyo Park ◽  
Dong Hyuk Sheen ◽  
Mi Kyoung Lim ◽  
Seung Cheol Shim
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Animal Models ◽  
Lupus Erythematosus ◽  
Systemic Lupus

scholarly journals IFN-γ Mediates the Development of Systemic Lupus Erythematosus

2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
Wenping Liu ◽  
Mengdi Li ◽  
Ziye Wang ◽  
Jibo Wang
Keyword(s):  
Gene Expression ◽  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Antigen Processing ◽  
Fiber Formation ◽  
The Body ◽  
Interferon Α ◽  
Systemic Lupus ◽  
Bioinformatics Analyses ◽  
Ifn Γ

Objective. Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect all organs in the body. It is characterized by overexpression of antibodies against autoantigen. Although previous bioinformatics analyses have identified several genetic factors underlying SLE, they did not discriminate between naive and individuals exposed to anti-SLE drugs. Here, we evaluated specific genes and pathways in active and recently diagnosed SLE population. Methods. GSE46907 matrix downloaded from Gene Expression Omnibus (GEO) was analyzed using R, Metascape, STRING, and Cytoscape to identify differentially expressed genes (DEGs), enrichment pathways, protein-protein interaction (PPI), and hub genes between naive SLE individuals and healthy controls. Results. A total of 134 DEGs were identified, in which 29 were downregulated, whereas 105 were upregulated in active and newly diagnosed SLE cases. GO term analysis revealed that transcriptional induction of the DEGs was particularly enhanced in response to secretion of interferon-γ and interferon-α and regulation of cytokine production innate immune responses among others. KEGG pathway analysis showed that the expression of DEGs was particularly enhanced in interferon signaling, IFN antiviral responses by activated genes, class I major histocompatibility complex (MHC-I) mediated antigen processing and presentation, and amyloid fiber formation. STAT1, IRF7, MX1, OASL, ISG15, IFIT3, IFIH1, IFIT1, OAS2, and GBP1 were the top 10 DEGs. Conclusions. Our findings suggest that interferon-related gene expression and pathways are common features for SLE pathogenesis, and IFN-γ and IFN-γ-inducible GBP1 gene in naive SLE were emphasized. Together, the identified genes and cellular pathways have expanded our understanding on the mechanism underlying development of SLE. They have also opened a new frontier on potential biomarkers for diagnosis, biotherapy, and prognosis for SLE.

scholarly journals EFEITOS DA CINESIOTERAPIA SOBRE A FORÇA DE PREENSÃO PALMAR EM INDIVÍDUOS COM DOENÇAS REUMÁTICAS

2018 ◽  
Vol 7 (1) ◽  
pp. 374-387
Author(s):  
Matheus Santos Gomes Jorge ◽  
Willian Guerra De Lima ◽  
Patrícia Rodigheri Vieira ◽  
Letícia Antoniolli Siiss ◽  
Caroline Zanin ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Handgrip Strength ◽  
The Body ◽  
Systemic Lupus ◽  
Artrite Reumatoide ◽  
Systemic Manifestations ◽  
The Right

Introdução: as doenças reumáticas apresentam manifestações musculoesqueléticas e sistêmicas que podem acometer quaisquer regiões do corpo. No caso das mãos, uma das manifestações é a diminuição da força de preensão palmar destes indivíduos. Objetivo: verificar os efeitos da cinesioterapia sobre a força de preensão palmar em indivíduos com doenças reumáticas. Material e métodos: estudo longitudinal e intervencionista com 24 indivíduos portadores de doenças reumáticas (osteoartrite, artrite reumatoide, fibromialgia, lúpus eritematoso sistêmico, esclerose sistêmica e dermatopolimiosite), com idade média de 50,23 anos. Os indivíduos realizaram 10 sessões de fisioterapia, baseadas em cinesioterapia, com exercícios globais e funcionais, 02 vezes por semana, com duração média de 50 minutos, de março de 2014 a novembro de 2015, na Clínica de Fisioterapia da Universidade de Passo Fundo, Passo Fundo/RS. As avaliações inicial e final envolveram a coleta de dados e a mensuração da força de preensão palmar, por meio da dinamometria manual. Resultados: observou-se que os indivíduos apresentaram melhora da força de preensão palmar, porém os resultados foram estatisticamente significativos apenas para a mão direita dos indivíduos com osteoartrite, para ambas as mãos dos indivíduos com artrite reumatoide e lúpus eritematoso sistêmico e para a força de preensão palmar geral dos indivíduos. Conclusão: o protocolo fisioterapêutico proposto produziu aumento da força de preensão palmar de indivíduos com doenças reumáticas.Palavras-chave: Força da mão. Doenças reumáticas. Fisioterapia. Reabilitação. Exercício. ABSTRACT: Introduction: rheumatic diseases present musculoskeletal and systemic manifestations that can affect any region of the body. In the case of the hands, one of the manifestations is the decrease of the handgrip strength of these individuals. Aim: to verify the effects of kinesiotherapy on handgrip strength in individuals with rheumatic diseases. Material and methods: longitudinal and interventional study with 24 individuals with rheumatic diseases (osteoarthritis, rheumatoid arthritis, fibromyalgia, systemic lupus erythematosus, systemic sclerosis and dermatopolymyositis), mean age 50.23 years. The individuals performed 10 sessions of physiotherapy, based on kinesiotherapy, with global and functional exercises, 02 times a week, with an mean duration of 50 minutes, from March 2014 to November 2015, at the Physiotherapy Clinic of Passo Fundo University, Passo Fundo/RS. The initial and final evaluations involved data collection and measurement of handgrip strength using manual dynamometry. Results: it was observed that the individuals presented improvement of the handgrip strength, but the results were statistically significant only for the right hand of individuals with osteoarthritis, for both hands of individuals with rheumatoid arthritis and systemic lupus erythematosus and for the handgrip strength of individuals. Conclusion: the proposed physiotherapeutic protocol produced an increase in the handgrip strength of individuals with rheumatic diseases.Keywords: Hand strength. Rheumatic diseases. Physical therapy specialty. Rehabilitation. Exercise.

Sign in / Sign up

Export Citation Format

Share Document